Paper Details

  1. Home
  2. Paper Details

[Clinical Efficacy of Decitabine Combined with or without Cytarabine-based Low Dose Regimen for Senile patients with Acute Myeloid Leukemia].

Author: DUYu, JingYu, LiPeng-Fei, LiuMo, PengChao-Jin, SunJun-Zhong, WangZhi-Hong, YaoYi-Bing, ZhouHong-Wei, ZhouMin-Hang

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Decitabine combined with or without cytarabine-based low-dose regimen showed promising results in treating geriatric acute myeloid leukemia, improving overall response rate and prolonging survival time.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: To investigate the therapeutic effectiveness and side effects of decitabine combined with or without cytarabine-based low dose regimen for acute myeloid leukemia in geratic patients. METHODS: Clinical data of 8 geratic patients (aged over 70 years) suffered from acute myeloid leukemia fr...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.7534/j.issn.1009-2137.2018.01.015

データ提供：米国国立医学図書館（NLM）

Decitabine: A Hopeful Treatment for Geriatric Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a formidable foe, like a fierce desert wind that can sweep through a life. This research examines the effectiveness of decitabine, a drug used in the treatment of AML, particularly in geriatric patients. The study investigates the therapeutic efficacy and side effects of decitabine, both alone and in combination with cytarabine-based low-dose regimens, in older adults with AML.

Decitabine Shows Promise for Treating Geriatric AML

The study reports encouraging results, indicating that decitabine, both alone and in combination with cytarabine, shows promise for treating geriatric AML. The researchers observed a significant improvement in overall response rate and a prolongation of overall survival time in patients receiving decitabine-based regimens. These findings suggest that decitabine could be a valuable treatment option for older adults battling AML, offering a glimmer of hope in their fight against this challenging disease.

Navigating the Complexities of AML Treatment in the Elderly

Treating AML in elderly patients presents unique challenges, akin to navigating a harsh desert landscape. The study highlights the importance of carefully considering the potential side effects of decitabine, while also recognizing its potential to improve treatment outcomes. It underscores the need for a personalized approach, taking into account individual patient factors and tailoring treatment regimens accordingly.

Dr. Camel's Conclusion

This research provides a valuable contribution to our understanding of AML treatment in geriatric patients. The findings suggest that decitabine-based regimens hold promise for improving treatment outcomes in this vulnerable population. The study underscores the importance of a balanced approach, carefully considering the potential benefits and risks of treatment while tailoring therapy to individual patient needs.
Date :
  1. Date Completed 2018-11-15
  2. Date Revised 2019-03-18
Further Info :

Pubmed ID

29397824

DOI: Digital Object Identifier

10.7534/j.issn.1009-2137.2018.01.015

SNS
PICO Info
in preparation
Languages

Chinese

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.